Kazumi Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazumi Kimura has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Kensaku Shibazaki
Department of Stroke Medicine, Kawasaki Medical School, Kurashiki City, Japan
34 shared publicationsYasuyuki Iguchi
30 shared publicationsTakeshi Inoue
Kawasaki Med Sch, Kurashiki, Japan
19 shared publicationsKazuo Minematsu
National Cerebral and Cardiovascular Cntr, Suita, Japan
15 shared publicationsJunya Aoki
12 shared publicationsTakenori Yamaguchi
11 shared publications
Latest Publications
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP195: Current Status of Reperfusion Therapy and Functional Outcome in Acute Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation: a Single-Center, Six-Year Experience of Consecutive 546 Patients
Background: The concept and tools of oral anticoagulation (OAC) therapy for preventing stroke in patients with non-valvular atrial fibrillation (NVAF) and their use as part of an acute treatment regimen in patients experiencing large-vessel occlusive stroke have grossly changed in the last 10 years. The aim of this study was therefore to evaluate the changes in reperfusion therapy and the clinical outcomes in acute ischemic stroke (AIS) patients with NVAF during a six-year time period. Methods: From March 2011 to March 2017, consecutive patients with AIS with NVAF who were admitted to our department were retrospectively analyzed. Patients were divided into three groups according to the year of their initial visit: 2011-2012 (n=136), 2013-2014 (n=206), and 2015-2016 (n=204). Reperfusion therapy including intravenous thrombolysis and endovascular therapy, and functional outcome, were compared between the three time periods. Results: The rate of reperfusion therapy increased steadily from 19.9% in 2011-2012 to 42.7% in 2015-2016 ( P < 0.0001). Parenchymal hematoma (PH) occurrence increased slightly from 5.9% in 2011-2012 to 9.8% in 2015-2016, but there was no significant difference ( P = 0.4301). Although there was no difference with respect to National Institutes of Health Stroke Scale (NIHSS) score at admission between the 2011-2012 and 2015-2016 groups (8 vs. 7, P = 0.3926), and CHA 2 DS 2 -VASc score was significantly higher in 2015-2016 compared with in 2011-2012 (4 vs 3, P = 0.0062), and discharge NIHSS score in 2015-2016 was significantly lower compared with that in 2011-2012 (2 vs. 4; P = 0.0093). The percentage of modified Rankin Scale 0-1 upon discharge was significantly higher in patients treated with reperfusion therapy than in those who were treated without it, among moderate-severe stroke patients (initial NIHSS ≥ 8) (15.4 vs. 2.8%, P = 0.0002). Moreover, hospital mortality rate significantly decreased from 11.0% in 2011-2012 to 3.4% in 2015-2016 ( P = 0.0167). Conclusions: According to the six-year trend, the use of reperfusion therapy increased steadily and this increase appears to be factor in improvement of functional outcome and mortality in patients with AIS with NVAF.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP195: Current Status of Reperfusion Therapy and Functional Outcome in Acute Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation: a Single-Center, Six-Year Experience of Consecutive 546 Patients
Background: The concept and tools of oral anticoagulation (OAC) therapy for preventing stroke in patients with non-valvular atrial fibrillation (NVAF) and their use as part of an acute treatment regimen in patients experiencing large-vessel occlusive stroke have grossly changed in the last 10 years. The aim of this study was therefore to evaluate the changes in reperfusion therapy and the clinical outcomes in acute ischemic stroke (AIS) patients with NVAF during a six-year time period. Methods: From March 2011 to March 2017, consecutive patients with AIS with NVAF who were admitted to our department were retrospectively analyzed. Patients were divided into three groups according to the year of their initial visit: 2011-2012 (n=136), 2013-2014 (n=206), and 2015-2016 (n=204). Reperfusion therapy including intravenous thrombolysis and endovascular therapy, and functional outcome, were compared between the three time periods. Results: The rate of reperfusion therapy increased steadily from 19.9% in 2011-2012 to 42.7% in 2015-2016 ( P < 0.0001). Parenchymal hematoma (PH) occurrence increased slightly from 5.9% in 2011-2012 to 9.8% in 2015-2016, but there was no significant difference ( P = 0.4301). Although there was no difference with respect to National Institutes of Health Stroke Scale (NIHSS) score at admission between the 2011-2012 and 2015-2016 groups (8 vs. 7, P = 0.3926), and CHA 2 DS 2 -VASc score was significantly higher in 2015-2016 compared with in 2011-2012 (4 vs 3, P = 0.0062), and discharge NIHSS score in 2015-2016 was significantly lower compared with that in 2011-2012 (2 vs. 4; P = 0.0093). The percentage of modified Rankin Scale 0-1 upon discharge was significantly higher in patients treated with reperfusion therapy than in those who were treated without it, among moderate-severe stroke patients (initial NIHSS ≥ 8) (15.4 vs. 2.8%, P = 0.0002). Moreover, hospital mortality rate significantly decreased from 11.0% in 2011-2012 to 3.4% in 2015-2016 ( P = 0.0167). Conclusions: According to the six-year trend, the use of reperfusion therapy increased steadily and this increase appears to be factor in improvement of functional outcome and mortality in patients with AIS with NVAF.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract TP34: Real World Efficacy of Endovascular Thrombectomy in Patients With Acute Cerebral Large Vessel Occlusion in Japan - First Report From RESCUE-Japan Registry 2
Introduction: Several randomized trials showed the endovascular thrombectomy (EVT) was effective in patients with acute cerebral large vessel occlusion, but the efficacy to general patients were unknown. Methods: Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry 2 was prospective registry of acute cerebral large vessel occlusion at centers in Japan. The patients were 20 years or elder and admitted within 24 hours after the onset of cerebral large vessel occlusion in both anterior and posterior circulation. Primary endpoint was good outcome defined by modified Rankin Scale (mRS) of 0-2 at 90 days after onset. Secondary endpoint was mortality. Adjusted odds ratio (OR) was estimated by logistic regression model accounted for potential confounders. Safety endpoints were all bleeding included intracerebral hemorrhage, gastrointestinal bleedings, recurrence of stroke, and other adverse events within 90 days. Results: Consecutive 2420 patients were recruited from October 2014 to September 2016, and follow-up ended at January 2017. Excluding 12 patients who did not meet inclusion criteria, 1281 patients were treated with EVT and 1127 were without. Mean age was 75 and 77 years in EVT and no-EVT groups, respectively. Posterior circulation accounted for 13% in both groups. Intravenous alteplase was administered in 47% and 32% of EVT and no-EVT groups, respectively. Good outcome was observed in 41.7% and 30.7% the EVT group and no-EVT group, respectively (pConclusions: EVT was shown effective in general patients with acute cerebral large vessel occlusion in terms of mRS and mortality at 90 days. The indication of EVT for posterior circulation should be reconsidered.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract TP34: Real World Efficacy of Endovascular Thrombectomy in Patients With Acute Cerebral Large Vessel Occlusion in Japan - First Report From RESCUE-Japan Registry 2
Introduction: Several randomized trials showed the endovascular thrombectomy (EVT) was effective in patients with acute cerebral large vessel occlusion, but the efficacy to general patients were unknown. Methods: Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry 2 was prospective registry of acute cerebral large vessel occlusion at centers in Japan. The patients were 20 years or elder and admitted within 24 hours after the onset of cerebral large vessel occlusion in both anterior and posterior circulation. Primary endpoint was good outcome defined by modified Rankin Scale (mRS) of 0-2 at 90 days after onset. Secondary endpoint was mortality. Adjusted odds ratio (OR) was estimated by logistic regression model accounted for potential confounders. Safety endpoints were all bleeding included intracerebral hemorrhage, gastrointestinal bleedings, recurrence of stroke, and other adverse events within 90 days. Results: Consecutive 2420 patients were recruited from October 2014 to September 2016, and follow-up ended at January 2017. Excluding 12 patients who did not meet inclusion criteria, 1281 patients were treated with EVT and 1127 were without. Mean age was 75 and 77 years in EVT and no-EVT groups, respectively. Posterior circulation accounted for 13% in both groups. Intravenous alteplase was administered in 47% and 32% of EVT and no-EVT groups, respectively. Good outcome was observed in 41.7% and 30.7% the EVT group and no-EVT group, respectively (pConclusions: EVT was shown effective in general patients with acute cerebral large vessel occlusion in terms of mRS and mortality at 90 days. The indication of EVT for posterior circulation should be reconsidered.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 159: Acute Aspirin Plus Cilostazol Dual Therapy for Non-cardioembolic Stroke Study (ADS)
Hypothesis: The aim of the present study was to investigate the efficacy and safety of antiplatelet (aspirin plus cilostazol) dual therapy for non-cardioembolic stroke patients within 48 h of symptom onset. Methods: ADS is an investigator initiated, a prospective, multicenter (34 hospitals in Japan), randomized, and an aspirin-controlled study. Acute stroke patients with non-cardioembolic stroke within 48 hours of onset were studied. Only patients with preadmission mRS score 0-2 were included. Subjects were randomly allocated to the combination therapy with aspirin 81-200mg plus cilostazol 200mg (Dual group) and the single therapy with aspirin 81-200mg (Aspirin group) for 14 days. After the 14 days, all patients took the cilostazol 200mg for 3 months. Primary outcomes include 1) the neurological worsening within 14 day of onset; and 2) the rates of transient ischemic attack (TIA), stroke recurrence, intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) within 14 days of onset. Secondary outcome included mRS score at 3 months after stroke. Results: 1,201 patients (796 [66%] men; median age [interquartile range], 69 [61-77] years) were randomized 1:1 to either the dual group or the aspirin group. Initial National Institutes of Health Stroke Scale score was similar as 2 (1-4) in both groups (p=0.617). As a primary outcome, the neurological worsening within 14 days was similarly observed in the dual and in the aspirin group (10.5% vs. 9.7%, P=0.701). The rates of TIA and stroke recurrence in the dual and in the aspirin group were also similar as 0.2% vs. 0.2% (p=1.000), and 1.2% vs. 1.3% (p=1.000), respectively. As a safety outcome, each group had one patient with ICH (0.2% vs. 0.2%, p=1.000). Only 1 patient (0.2%) in the dual group complained of SAH within 14 days of stroke onset, though it was asymptomatic (p=1.000). Regarding the secondary outcome, although preadmission mRS score of 0 was infrequent in the dual group (84% vs. 89%, p=0.054), the rate of mRS 0-1 at 3 months seemed to be frequent in the dual group than aspirin group (69% vs. 64% p=0.075). Conclusions: Dual antiplatelet therapy using cilostazol and aspirin does not reduce the rate of short-term neurological worsening. However, this combined therapy may improve the clinical outcome at 3 months of onset.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 159: Acute Aspirin Plus Cilostazol Dual Therapy for Non-cardioembolic Stroke Study (ADS)
Hypothesis: The aim of the present study was to investigate the efficacy and safety of antiplatelet (aspirin plus cilostazol) dual therapy for non-cardioembolic stroke patients within 48 h of symptom onset. Methods: ADS is an investigator initiated, a prospective, multicenter (34 hospitals in Japan), randomized, and an aspirin-controlled study. Acute stroke patients with non-cardioembolic stroke within 48 hours of onset were studied. Only patients with preadmission mRS score 0-2 were included. Subjects were randomly allocated to the combination therapy with aspirin 81-200mg plus cilostazol 200mg (Dual group) and the single therapy with aspirin 81-200mg (Aspirin group) for 14 days. After the 14 days, all patients took the cilostazol 200mg for 3 months. Primary outcomes include 1) the neurological worsening within 14 day of onset; and 2) the rates of transient ischemic attack (TIA), stroke recurrence, intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) within 14 days of onset. Secondary outcome included mRS score at 3 months after stroke. Results: 1,201 patients (796 [66%] men; median age [interquartile range], 69 [61-77] years) were randomized 1:1 to either the dual group or the aspirin group. Initial National Institutes of Health Stroke Scale score was similar as 2 (1-4) in both groups (p=0.617). As a primary outcome, the neurological worsening within 14 days was similarly observed in the dual and in the aspirin group (10.5% vs. 9.7%, P=0.701). The rates of TIA and stroke recurrence in the dual and in the aspirin group were also similar as 0.2% vs. 0.2% (p=1.000), and 1.2% vs. 1.3% (p=1.000), respectively. As a safety outcome, each group had one patient with ICH (0.2% vs. 0.2%, p=1.000). Only 1 patient (0.2%) in the dual group complained of SAH within 14 days of stroke onset, though it was asymptomatic (p=1.000). Regarding the secondary outcome, although preadmission mRS score of 0 was infrequent in the dual group (84% vs. 89%, p=0.054), the rate of mRS 0-1 at 3 months seemed to be frequent in the dual group than aspirin group (69% vs. 64% p=0.075). Conclusions: Dual antiplatelet therapy using cilostazol and aspirin does not reduce the rate of short-term neurological worsening. However, this combined therapy may improve the clinical outcome at 3 months of onset.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP329: T2 Spotty Sign on Magnetic Resonance Imaging Should be Associated With Hematoma Expansion in Patients With Intracerebral Hemorrhage
Introduction: The presence of spotty lesions in ICH on T2, which we determined as a spotty sign, is occasionally observed. Our study was aimed to determine whether the presence of spotty sign on T2 could be an independent prognostic marker for hematoma expansion in ICH patients. Method: Patients with spontaneous ICH were retrospectively identified and their MRI images were reviewed. The spotty sign was defined as “the small lesions don’t matter the size and shape in the hematoma on MRI T2-weighted images”. Significant hematoma expansion was defined as an absolute increase of hematoma volume of >6.0mL or an increase in hematoma volume of >33%. Neurological severity was evaluated using the National Institutes of Health Stroke Scale (NIHSS) scores at admission. Univariate and multivariable logistic regression analyses were applied to assess the presence of the spotty sign and its association with hematoma expansion. Results: A total of 145 patients were enrolled, and 20 (14%) showed hematoma expansion, and 58(40%) had T2 spotty sign (Figure). Patients with hematoma expansion had a significantly larger hematoma volume (11.74ml vs 6.07ml, PConclusion: The presence of a spotty sign on the initial MRI T2 scan should be associated with hematoma expansion in ICH patients.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract WP329: T2 Spotty Sign on Magnetic Resonance Imaging Should be Associated With Hematoma Expansion in Patients With Intracerebral Hemorrhage
Introduction: The presence of spotty lesions in ICH on T2, which we determined as a spotty sign, is occasionally observed. Our study was aimed to determine whether the presence of spotty sign on T2 could be an independent prognostic marker for hematoma expansion in ICH patients. Method: Patients with spontaneous ICH were retrospectively identified and their MRI images were reviewed. The spotty sign was defined as “the small lesions don’t matter the size and shape in the hematoma on MRI T2-weighted images”. Significant hematoma expansion was defined as an absolute increase of hematoma volume of >6.0mL or an increase in hematoma volume of >33%. Neurological severity was evaluated using the National Institutes of Health Stroke Scale (NIHSS) scores at admission. Univariate and multivariable logistic regression analyses were applied to assess the presence of the spotty sign and its association with hematoma expansion. Results: A total of 145 patients were enrolled, and 20 (14%) showed hematoma expansion, and 58(40%) had T2 spotty sign (Figure). Patients with hematoma expansion had a significantly larger hematoma volume (11.74ml vs 6.07ml, PConclusion: The presence of a spotty sign on the initial MRI T2 scan should be associated with hematoma expansion in ICH patients.
- 1 April 2017
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 26 (4) , 888
Feasibility of using magnetic resonance imaging as a screening tool for acute stroke thrombolysis
- 1 April 2017
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 26 (4) , 888
Feasibility of using magnetic resonance imaging as a screening tool for acute stroke thrombolysis
- 1 September 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 368, 160-164
Characteristics of subcortical infarction due to distal MCA penetrating artery occlusion
- 1 September 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 368, 160-164
Characteristics of subcortical infarction due to distal MCA penetrating artery occlusion
- 3 June 2016
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 25 (9) , 2237-2242
Differences in Clinical Characteristics between Patients with Transient Ischemic Attack Whose Symptoms Do and Do Not Persist on Arrival
- 3 June 2016
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 25 (9) , 2237-2242
Differences in Clinical Characteristics between Patients with Transient Ischemic Attack Whose Symptoms Do and Do Not Persist on Arrival
- 13 April 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 365, 74-75
Aspirin, but not clopidogrel, ameliorates vasomotor symptoms due to essential thrombocythemia: A case report
- 13 April 2016
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 365, 74-75
Aspirin, but not clopidogrel, ameliorates vasomotor symptoms due to essential thrombocythemia: A case report
- 1 January 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 348 (1-2) , 195-200
The susceptibility vessel sign at the proximal M1: A strong predictor for poor outcome after intravenous thrombolysis
- 1 January 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 348 (1-2) , 195-200
The susceptibility vessel sign at the proximal M1: A strong predictor for poor outcome after intravenous thrombolysis
- 1 January 2014
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 54 (6) , 480-483
The importance of transient neurological attacks (TNAs)
Transient neurological attacks (TNAs) are attacks with temporary (< 24 h) neurological symptoms, and reported in 1975. Ischemic cerebral infarction often occurres after transient neurological symptoms which are not sometimes involved in transient ischemic attack (TIA) criteria. The purpose of this study was to clarity transient neurological symptoms before the onset of ischemic stroke. Consecutive acute stroke and TIA patients within 7 days of onset between July 2011 and December 2012 were studied. Questionnaire survey of transient neurological symptoms was done and we investigated the history of transient neurological symptoms and divided the patients into three groups, TIA group (history of TIA), TNAs group (history of TNAs), and no past history group. We compared clinical characteristics, the rate of posterior circulation lesions, and number of attacks among three groups. 184 patients (male 112 patients, mean 73 years old) were enrolled into the present study. TNAs group had 13 (7%) patients, and TIA had 20 (11%). Neurological symptoms of TNAs group were 5 (38%) transient dizziness, 3 (23%) disturbance of consciousness, 2 (23%) weakness of legs, 1 (8%) sensory disturbance of legs, 1 (8%) gait disturbance, and 1 (8%) sensory disturbance of lips. Five (38%) TNAs group had multiple attacks. In 33 transient neurological symptom patients, 17 (52%) patients did not have hospital visit, and 7 (21%) patient did not have antiplatelet and anticoagulant drug. TNAs group more frequently had hyperlipidemia, diabetes mellitus, and posterior circulation lesions among three groups. 20% posterior circulation lesion patients had TNAs history, and posterior circulation might be examined in TNAs patients.
- 1 January 2014
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 54 (6) , 480-483
The importance of transient neurological attacks (TNAs)
Transient neurological attacks (TNAs) are attacks with temporary (< 24 h) neurological symptoms, and reported in 1975. Ischemic cerebral infarction often occurres after transient neurological symptoms which are not sometimes involved in transient ischemic attack (TIA) criteria. The purpose of this study was to clarity transient neurological symptoms before the onset of ischemic stroke. Consecutive acute stroke and TIA patients within 7 days of onset between July 2011 and December 2012 were studied. Questionnaire survey of transient neurological symptoms was done and we investigated the history of transient neurological symptoms and divided the patients into three groups, TIA group (history of TIA), TNAs group (history of TNAs), and no past history group. We compared clinical characteristics, the rate of posterior circulation lesions, and number of attacks among three groups. 184 patients (male 112 patients, mean 73 years old) were enrolled into the present study. TNAs group had 13 (7%) patients, and TIA had 20 (11%). Neurological symptoms of TNAs group were 5 (38%) transient dizziness, 3 (23%) disturbance of consciousness, 2 (23%) weakness of legs, 1 (8%) sensory disturbance of legs, 1 (8%) gait disturbance, and 1 (8%) sensory disturbance of lips. Five (38%) TNAs group had multiple attacks. In 33 transient neurological symptom patients, 17 (52%) patients did not have hospital visit, and 7 (21%) patient did not have antiplatelet and anticoagulant drug. TNAs group more frequently had hyperlipidemia, diabetes mellitus, and posterior circulation lesions among three groups. 20% posterior circulation lesion patients had TNAs history, and posterior circulation might be examined in TNAs patients.